MMV welcomes proposals in the following four areas:

1. Compounds addressing the key priorities of the malaria eradication agenda
   New families of molecules in the hit-to-lead and lead optimization stages are sought that either:
   - kill or reactivate hypnozoites for use as part of a *P. vivax* radical cure;
   - have dual activity against asexual and sexual stages (gametocytes) for treatment and transmission blocking;
   - are novel and without G6PD deficiency liabilities.

2. Assays addressing liver stage *vivax*
   - Novel, robust and validated *in vitro or in vivo* models of vivax liver stages are sought that are suitable for immediate compound testing. Please see MMV’s website for specific details.

3. Asexual liver and blood stages
   Novel chemical series with EC50<1µM and which have one or more of the following key features:
   - A novel mechanism of action;
   - A long half-life (ideally >4h in rodents) and confirmed *in vivo* efficacy;
   - No evidence of genotoxic or developmental issues along with a plan to continuously examine these aspects during the Discovery phase and also once a preclinical candidate is selected.
   - For advanced series, we are seeking compounds with, ideally, a predicted human half-life >100h and a predicted single human dose <1g.

   Please see the published MMV Target Candidate Profiles on MMV’s website for more information. Early target validation falls outside of our mandate.

4. Resistant strains
   To help select future antimalarial candidate drugs, we would like to hear from groups who have stable parasite cultures that show significant resistance to any of the drugs listed below:
   - Piperaquine, Pyronaridine, Mefloquine, Amodiaquine, Lumefantrine

   If resistance is confirmed then MMV would welcome the opportunity to add a resistant clone to our screening panel.

Application templates are available at: www.mmv.org

Deadline for applications: 31 March 2015